Analyst Kallum Titchmarsh of Morgan Stanley maintained a Buy rating on Tempus AI, Inc. Class A, retaining the price target of $85.00.
Meet Samuel – Your Personal Investing Prophet
Explore TEMT for 2X leverage on TEMKallum Titchmarsh has given his Buy rating due to a combination of factors tied to Tempus AI’s diversified and durable growth profile. He highlights that revenue expansion is coming from multiple segments, including strong oncology testing momentum, robust MRD growth despite a still-limited salesforce, and healthy demand in comprehensive genomic profiling, all of which support confidence in the medium‑term outlook.
At the same time, he views 2026 guidance as achievable, with upside potential not fully reflected in current forecasts, especially as adjusted EBITDA inflects toward sustained profitability. He also notes that Tempus trades at a discount to precision oncology peers despite its attractive topline trajectory and emerging operating leverage, which, together with solid data‑segment bookings and a reassuring early‑2026 outlook, underpins his Overweight (Buy) stance on the shares.
According to TipRanks, Titchmarsh is a 3-star analyst with an average return of 3.7% and a 37.70% success rate. Titchmarsh covers the Healthcare sector, focusing on stocks such as Stevanato Group, Danaher, and GRAIL Inc.
In another report released on February 19, Mizuho Securities also initiated coverage with a Buy rating on the stock with a $100.00 price target.